CHUGAI PHARMACEUTICAL CO.,LTD. FY2026 Q2 Earnings Report

Financial Highlights

• Net Sales: ¥663.33B
• Operating Income: ¥319.62B
• Net Income: ¥231.75B
• EPS: ¥140.82

Income Statement

Balance Sheet

Cash Flow Statement

Profitability Ratios

Year-over-Year Comparison

Share Information

Dividend Information

Full Year Forecast

---

AI Financial Analysis

Executive Summary

Verdict: Strong H1 (FY2026 Q2 cumulative) beat driven by double‑digit top-line growth and margin expansion, with solid cash conversion and a fortress balance sheet. Revenue rose 14.7% YoY to 6,633.3, and operating income increased 16.9% YoY to 3,196.2. Gross profit grew to 4,663.2, underpinning a gross margin of 70.3%, up about 70 bps YoY. Operating margin reached 48.2%, expanding roughly 90 bps from 47.3% in the prior period, reflecting favorable mix and operating leverage. Net income advanced 19.2% YoY to 2,317.5, and net margin improved by roughly 130 bps to 34.9%. DuPont shows ROE at 11.4% (Net Margin 34.9% × Asset Turnover 0.271 × Leverage 1.21x), with the step‑up primarily margin‑driven while leverage remains conservative. Earnings quality is sound: OCF of 2,491.0 exceeded net income (OCF/NI 1.07x), and the accruals ratio is a healthy -0.7%. Free cash flow came in at 2,130.5, supporting distributions and reinvestment. Liquidity is exceptional (current assets 17,041.9 vs total liabilities 4,222.5), and equity ratio is 82.8%, limiting solvency risk. Cash returned to shareholders was significant, with Q2 DPS at ¥66 (payout ratio 47.8%) and FCF coverage of the interim dividend at 1.92x. Working capital intensity is elevated (DSO 210 days, DIO 588 days, CCC 501 days), which is a key watch‑item despite the strong cash generation this period. The extended CCC, alongside a rise in accounts payable, suggests deliberate inventory and payables management that supported OCF, warranting monitoring for normalization. Forward‑looking, margin momentum and cash generation position the company well to fund R&D and shareholder returns, though sustained working capital discipline will be critical to preserve cash flow quality.

Profitability Analysis

ROE (11.4%) = Net Margin (34.9%) × Asset Turnover (0.271) × Leverage (1.21x). Net margin expanded by ~130 bps YoY on a 70 bps gross margin lift and operating margin up ~90 bps to 48.2%, indicating favorable mix and operating leverage. Interest burden at 1.03 signals net finance income/low interest costs; tax burden at 0.704 is standard. The improvement is primarily operational and appears sustainable near term, while conservative leverage limits risk. SG&A growth trailed revenue, reinforcing operating leverage.

Growth Assessment

Top-line growth of 14.7% YoY to 6,633.3 translated into a 16.9% YoY increase in operating income to 3,196.2, highlighting positive operating leverage. Gross margin expanded to 70.3% and operating margin to 48.2%, supporting a 19.2% rise in net income to 2,317.5. The breadth of margin improvement suggests mix tailwinds and scale efficiencies, with profitability rising faster than revenue. With strong OCF (2,491.0) and FCF (2,130.5), the company retains ample capacity to fund pipeline and capacity investments while maintaining dividends.

Financial Health

Balance sheet is very strong: equity ratio 82.8%, D/E 0.21x, and substantial current assets (17,041.9) vs total liabilities (4,222.5). No warning thresholds breached (Current Ratio >> 1.0; D/E well below 2.0). Low maturity mismatch risk given large liquid asset base vs short-term obligations. Payables growth aids liquidity near term but could reverse.

Notable B/S Changes

Accounts Payable: +334.5 (+26.3%) - Extended supplier credit supporting working capital; monitor for normalization impact on OCF. Other Current Liabilities: -617.9 (-32.6%) - Reduction eases short-term obligations, improving near-term liquidity.

Cash Flow Quality

OCF of 2,491.0 exceeds NI of 2,317.5 (OCF/NI 1.07x), and accruals ratio is -0.7%, both signaling high earnings quality. FCF of 2,130.5 comfortably covers interim dividends and reinvestment. Elevated DSO/DIO and higher payables supported OCF; watch for potential WC reversal that could temper cash generation.

Dividend Sustainability

Interim DPS ¥66 equates to a 47.8% payout ratio, within the <60% benchmark. FCF coverage of the interim dividend is 1.92x, indicating headroom. Given strong OCF and low leverage, dividend capacity appears well supported.

Risk Assessment

Business risks include Extended cash conversion cycle (CCC 501 days) could tie up cash and pressure OCF if growth slows., High inventory days (DIO 588) increase obsolescence and write-down risk if demand shifts., High receivable days (DSO 210) elevate collection risk and cash flow timing uncertainty., Margin sensitivity to product mix and pricing in key therapeutic areas..

Financial risks include Working capital reliance on elevated payables; normalization could reduce OCF., Tax burden at 29.6% leaves limited room for further structural tax benefits., Dividend outflows timing vs. FCF may create intra-year cash swings..

Key concerns include ⚠️ HIGH_RECEIVABLE_DAYS (DSO 210): Root cause—long billing/collection cycles typical for pharma distribution and potential export terms; Context—well above benchmark; Impact—can delay cash realization and raise credit exposure., ⚠️ HIGH_INVENTORY_DAYS (DIO 588): Root cause—strategic inventory build to ensure supply continuity and support growth; Context—significantly higher than norms; Impact—working capital drag and potential write-down risk if demand/fx shifts., ⚠️ LONG_CCC (501 days): Root cause—combination of high DSO and very high DIO outweighing payables; Context—materially above benchmark; Impact—elevated funding needs for growth and potential volatility in OCF if WC reverses., ⚠️ HIGH_INVENTORY_DAYS (repeat flag): Reinforces the above—inventory is the principal driver of the extended CCC and the most material WC risk..

Investment Implications

Key takeaways include Quality beat: revenue +14.7% YoY with operating margin expanding ~90 bps to 48.2%., ROE at 11.4% is margin-led with low leverage (1.21x), indicating resilient profitability on a conservative balance sheet., Cash generation strong (OCF/NI 1.07x; FCF 2,130.5), supporting dividends and reinvestment., Working capital intensity (DSO 210, DIO 588) is the main overhang; OCF sustainability hinges on inventory and receivable normalization..

Metrics to watch include Gross and operating margin trajectory vs. product mix shifts, OCF/NI ratio sustainability and WC contribution by component, DSO/DIO/CCC trends and accounts payable normalization, Capex and intangible additions vs. FCF to gauge reinvestment capacity.

Regarding relative positioning, Within Japan pharma, profitability and balance sheet strength are top-tier with exceptional margins and low leverage; the principal relative weakness is working capital efficiency, which trails best-in-class peers.